Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Terminalia glaucescens* is a plant species whose aqueous leaf extract (ALET) is being investigated for its potential chemopreventive and chemotherapeutic properties, particularly in liver and urinary bladder cancers. The extract is rich in phenolic compounds and flavonoids, exhibiting significant antioxidant and free-radical-scavenging activities. In preclinical studies, ALET has demonstrated antiproliferative effects against human liver (HepG2) and urinary bladder (MC-T11) cancer cell lines. Its mechanism of action involves ATP depletion, reduction of glutathione levels, and mitochondrial toxicity, leading to its classification as a potential "mitocan" (mitochondria-targeting anticancer agent). Research is primarily conducted by academic institutions such as the University of Ibadan and the University of California, Los Angeles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Terminalia glaucescens.